Last reviewed · How we verify
NCT04120844
Effectiveness of Motivational Interviewing on Improving Care for Type 2 Diabetes Mellitus Patients in China
NA trial testing Motivational interviewing (MI)-based patient empowerment program (PEP) in Diabete Type 2 in 225 participants. Completed in 26 September 2019.
1 April 2017
Quick facts
| Lead sponsor | The University of Hong Kong-Shenzhen Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | health services research |
| Enrollment | 225 |
| Start date | 1 May 2016 |
| Primary completion | 1 April 2017 |
| Estimated completion | 26 September 2019 |
Drugs / interventions tested
- Motivational interviewing (MI)-based patient empowerment program (PEP)
- Traditional lecture style health education
Conditions studied
- Diabete Type 2 — all drugs for Diabete Type 2 →
Sponsor
The University of Hong Kong-Shenzhen Hospital
Who can join
Adults 18 to 75, any sex, with Diabete Type 2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The International Diabetes Federation estimated that there were nearly 110 million diabetes mellitus (DM) patients in China, which was the highest number recorded in the world. In response to the rising patient numbers and costs, the Chinese government has invested heavily in primary healthcare, with the goal of improving chronic disease management in the primary care settings. A key part of the primary care improvement program prioritizes health education as a route to lifestyle modification. Although the content and modes of delivery vary enormously, most of the programs focused on providing information rather than facilitating patient change. The impacts of traditional patient education on lifestyle modification and changes in psychological status have been reported to be suboptimal. It is therefore necessary to rethink and explore a more structured, patient-centered approach to health education at improving the outcomes of DM control. Motivational interviewing (MI) is a collaborative, patient-centered counseling approach that aims to elicit behavior change.The focus of MI is to find and resolve the ambivalence, improve patients' perception of the importance of behavior change, and support them to make the change. MI provides a structural framework with guiding principles that can be easily followed by the primary care doctors. Some studies show that MI can contribute to improve healthy eating, weight control and increases in physical activity, but most research focused on intermediate outcome measures and did not evaluate the readiness to change. MI can be utilized by a variety of healthcare providers, which makes it adaptable for different culture and clinical settings. The effectiveness of MI in Chinese diabetic patients remains uncertain.Therefore, in this study, we adopted the group MI approach and developed a patient empowerment program (PEP) utilizing the techniques and framework of MI. We compared this to the most common form of DM education in China, a lecture on DM to patients and their carers in a hospital lecture theatre in a didactic manner. The study aimed to assess the effectiveness of the MI approach in terms of patient lifestyle modification and improving DM controls compared to the control group in a non-blinded randomized controlled trial (RCT) design.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effectiveness of motivational interviewing on improving Care for Patients with type 2 diabetes in China: A randomized controlled trial.
Li Z, Chen Q, Yan J, Liang W, et al · · 2020 · cited 17× · PMID 31973759 · DOI 10.1186/s12913-019-4776-8
Verify or expand the search:
- PubMed search for NCT04120844
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabete Type 2
Currently open trials in the same condition.
- NCT07506356 — Investigation of Gastric Emptying by Gastric Ultrasonography in Diabetic Patients Treated With GLP-1 Receptors · recruiting
- NCT07467460 — Precision Medicine and Neurodegenerative Diseases: Advanced Systems for the Diagnosis and Treatment of Parkinson's Disea · recruiting
- NCT07469943 — The Effect of Sodium Glucose Co-trnasportert Type 2 Inhibitors on Arterial Stiffness, Endothelial Glycocalyx Thickness a · recruiting
- NCT07495787 — Magnetic Compression Anastomosis Procedure for Partial Jejunoileal Anastomosis: Assessing the Viability of an Innovative · NA · recruiting
- NCT07212075 — Precision Subclassification of Mental Health in Diabetes: Digital Twins for Precision Mental Health to Track Subgroups · recruiting
Other The University of Hong Kong-Shenzhen Hospital trials
Trials by the same sponsor.
- NCT07013461 — International Collaborative Study on AJCC/UICC TNM-10 for Nasopharyngeal Cancer · not yet recruiting
- NCT07050706 — The Correlation Between Serum PRMT5 Level and Cardiac Ultrasound Indicators in Patients With Heart Failure · enrolling by invitation
- NCT07015554 — Serum IGF1 on Female HFpEF Patients · enrolling by invitation
- NCT06314087 — Individualized Neoantigen Therapy with Unusual Radiotherapy Enhancement (iNATURE) · Phase 2 · recruiting
- NCT06593223 — Non-invasive Filling Pressure(NIFP) Device Based on Low Frequency Heart Sound in Assessment of Congestion in Heart Failu · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04120844 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The University of Hong Kong-Shenzhen Hospital
- Last refreshed: 9 October 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04120844.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing